-+ 0.00%
-+ 0.00%
-+ 0.00%

Baird Maintains Outperform on Alto Neuroscience, Lowers Price Target to $36

Benzinga·05/18/2026 17:04:47
Listen to the news
Baird analyst Brian Skorney maintains Alto Neuroscience (NYSE:ANRO) with a Outperform and lowers the price target from $38 to $36.